What are the management strategies for Type 1 and Type 2 Hepatorenal Syndrome (HRS)?

Types of Hepatorenal Syndrome and Their Management

Classification of HRS

Hepatorenal syndrome is classified into two distinct types based on the rapidity and severity of renal dysfunction, each requiring different management approaches.

Type 1 HRS (HRS-AKI)

• Type 1 HRS is characterized by rapid, progressive renal impairment with serum creatinine increasing ≥100% to >2.5 mg/dL in less than 2 weeks, representing an acute kidney injury pattern 1, 2
• Median survival without treatment is approximately 1 month, making this a medical emergency requiring immediate intervention 2
• Bacterial infections, particularly spontaneous bacterial peritonitis, are the most important precipitating factors 2

Type 2 HRS (HRS-CKD)

• Type 2 HRS features stable or slowly progressive renal impairment with a more chronic course and median survival of 6 months 2, 3
• The main clinical manifestation is refractory ascites that responds poorly to diuretic therapy 3
• This form has a better prognosis than Type 1 but still requires definitive treatment 1

---

Management of Type 1 HRS

First-Line Pharmacological Treatment

Terlipressin plus albumin is the first-line pharmacological treatment for Type 1 HRS and should be initiated immediately upon diagnosis.

Terlipressin Dosing Protocol

• Start with terlipressin 1 mg IV bolus every 4-6 hours combined with albumin 1, 4
• Administer albumin 1 g/kg on day 1 (maximum 100 g), followed by 20-40 g/day thereafter 5, 6
• If serum creatinine does not decrease by at least 25% after 3 days, increase terlipressin dose stepwise to a maximum of 2 mg every 4 hours 1, 4
• Continue treatment until serum creatinine decreases below 1.5 mg/dL (133 μmol/L) or for a maximum of 14 days 1, 5
• Discontinue treatment within 14 days if there is no response or only partial response 1

Treatment Response Monitoring

• Monitor for progressive reduction in serum creatinine, increased arterial pressure, increased urine volume, and increased serum sodium concentration 5
• Median time to response is approximately 14 days, with shorter response times in patients with lower baseline serum creatinine 5
• Predictors of good response include serum bilirubin <10 mg/dL before treatment and an increase in mean arterial pressure >5 mmHg at day 3 of treatment 5
• In the CONFIRM trial, 29.1% of patients achieved verified HRS reversal with terlipressin compared to 15.8% with placebo 6

Important Safety Considerations

• Monitor for ischemic complications including arrhythmia, angina, splanchnic ischemia, and digital ischemia 5
• Exclude patients with shock, sepsis, uncontrolled bacterial infection, or baseline serum creatinine >7.0 mg/dL 6
• Vasopressor use is prohibited during terlipressin treatment 6

Alternative Vasoconstrictor Regimens

In regions where terlipressin is unavailable, midodrine plus octreotide plus albumin serves as an alternative treatment option.

Midodrine/Octreotide/Albumin Protocol

• Midodrine: Start at 7.5 mg orally three times daily, titrate up to 12.5-15 mg three times daily 4, 5
• Octreotide: 100-200 μg subcutaneously three times daily 4, 5
• Albumin: 10-20 g IV daily for up to 20 days 4, 5
• This combination can be administered outside an ICU setting and even at home 4
• Significantly improved short-term survival and renal function in both HRS Type 1 and Type 2 in observational studies 7

Norepinephrine Alternative

• Norepinephrine (0.5-3 mg/h) with albumin is equally effective as terlipressin but requires ICU monitoring 5, 2
• Goal is to increase mean arterial pressure by 15 mmHg 1, 4
• Success rate of 83% reported in pilot studies 4
• May be administered outside ICU settings with close monitoring according to recent recommendations 2

Non-Pharmacological Interventions

Transjugular Intrahepatic Portosystemic Shunt (TIPS)

• TIPS may improve renal function in selected patients with Type 1 HRS who have responded partially to medical therapy 5
• However, there are insufficient data to support TIPS as a standard treatment for Type 1 HRS, and many patients have contraindications 1
• Applicability is very limited due to contraindications in most patients with advanced liver disease 1

Renal Replacement Therapy

• Renal replacement therapy may be useful in patients who do not respond to vasoconstrictor therapy and who fulfill criteria for renal support 1
• Continuous venovenous hemofiltration is preferable to intermittent hemodialysis in hemodynamically unstable patients 4
• RRT should not be considered first-line therapy and is primarily used as a bridge to liver transplantation 4, 8
• Both hemodialysis and continuous venous hemofiltration have been used, but published information is very scant 1

Definitive Treatment

Liver transplantation is the definitive treatment for Type 1 HRS and should be pursued urgently in all eligible candidates.

• Liver transplantation is the treatment of choice for Type 1 HRS, with survival rates of approximately 65% 1, 4
• Patients with Type 1 HRS should be given priority for transplantation due to high mortality while on the waiting list 1, 5
• Treatment of HRS before transplantation with vasoconstrictors may improve outcomes after transplantation 1, 4
• There is no advantage in using combined liver-kidney transplantation versus liver transplantation alone, except in patients who have been under prolonged renal support therapy (>12 weeks) 1
• The reduction in serum creatinine levels after treatment and the related decrease in the MELD score should not change the decision to perform liver transplantation since the prognosis after recovering from Type 1 HRS is still poor 1, 4

---

Management of Type 2 HRS

Pharmacological Management

• The same vasoconstrictor regimens used for Type 1 HRS can be applied to Type 2 HRS, though the urgency is less acute 1
• Terlipressin plus albumin remains the first-line option when pharmacological treatment is indicated 1

TIPS for Type 2 HRS

• TIPS has been shown to improve renal function and control of ascites in patients with Type 2 HRS 1, 4
• TIPS is more applicable in Type 2 HRS than Type 1 HRS due to the more stable clinical condition of these patients 1
• However, TIPS has not been specifically compared with standard medical therapy in controlled trials 1

Definitive Treatment

• Liver transplantation is the treatment of choice for Type 2 HRS, with similar survival rates as Type 1 HRS (approximately 65%) 1, 4
• Treatment of HRS before transplantation may improve post-transplant outcomes 1, 4

---

Prevention Strategies

Prevention of HRS should be implemented in high-risk patients with advanced cirrhosis.

Antibiotic Prophylaxis

• Norfloxacin 400 mg/day reduces the incidence of HRS in advanced cirrhosis 1, 4, 5
• Albumin infusion together with antibiotics for spontaneous bacterial peritonitis reduces the risk of developing HRS and improves survival 5

Pentoxifylline

• Pentoxifylline 400 mg three times daily prevents HRS development in patients with severe alcoholic hepatitis 1, 4, 5
• Short-term treatment (4 weeks) was shown to prevent HRS in a randomized double-blind study 1

---

Critical Pitfalls to Avoid

• Do not delay liver transplantation evaluation in any patient with HRS, regardless of response to medical therapy 1
• Avoid the triple combination of ACE inhibitors, ARBs, and aldosterone antagonists due to risk of hyperkalemia 5
• Do not use renal replacement therapy as stand-alone therapy unless patients are candidates for liver transplantation 4, 8
• Do not allow improvement in serum creatinine and MELD score after vasoconstrictor therapy to delay transplantation decisions, as prognosis remains poor 1, 4
• Ensure diagnostic paracentesis is performed to rule out spontaneous bacterial peritonitis before diagnosing HRS 4